TCS, Anand Rathi Wealth, and Tata Elxsi are in focus following their Q1 FY26 earnings, while Glenmark Pharma made headlines with a $1.2 billion licensing deal with AbbVie. Birla Corporation secured a limestone block in Rajasthan, and IREDA may see action on sectoral cues. Watch for earnings momentum, strategic tie-ups, and regulatory updates to drive stock-specific moves. Track key corporate developments ahead of Friday’s session.
